ATC Group: C10AA01 Simvastatin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C10AA01 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C10 Lipid modifying agents
3 C10A Lipid modifying agents, plain
4 C10AA HMG CoA reductase inhibitors
5 C10AA01 Simvastatin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg

Active ingredients in C10AA01

Active Ingredient Description
Simvastatin

Simvastatin has a potent activity in inhibiting HMG-CoA reductase (3-hydroxy–3-ethylglutaryl-CoA-reductase). Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations.

Related product monographs

Title Information Source Document Type  
SIMCARD Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
SIMVASTATIN Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZOCOR Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Albania (AL)

Australia (AU)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

Nigeria (NG)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.